Category - Markets

Maxim Group lowered its price target for Bio-Path Holdings (NASDAQ:BPTH) to $2 from $5, citing the company’s data trough ahead. The stock was changing hands at $1.72 on Wednesday afternoon. Analyst Jason McCarthy writes...

Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday. “Relative to all...

Maxim Group lowered its price target for Galena Biopharma (NASDAQ:GALE) to $1 from $2, citing a shift in the company’s pipeline focus. The stock closed at 46 cents on Tuesday. At the end of June, an Independent Data...

Maxim Group lowered its price target for Omeros (NASDAQ:OMER) to $19 from $30, citing a higher risk value from its three valuation models. The stock closed at $13.38 on Tuesday. Analyst Jason Kolbert writes that sales...

Maxim Group raised it price target for Sophiris Bio (NASDAQ:SPHS) to $6 from $4, citing better data of the company’s topsalysin drug candidate. The stock closed at $5.04 on Tuesday. As the datasets for topsalysin...

Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) reported positive results from a Phase 2 study of ATB-346 in osteoarthritis (OA). Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a...

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday. “We believe the current valuation...

Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday. “We believe the company’s anticalin platform has broad...

Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday. “At the current valuation, we believe that Radius is back to an overvalued...

William Blair downgraded EndoChoice Holdings (NYSE:GI) to “market perform,” citing lower-than-expected second quarter results and reduced guidance. The stock closed at $5.26 on Wednesday. “While we continue to view...